US FDA Maps Out Novel Path For Developers Of Next Gen Sequencing Products
This article was originally published in SRA
Executive Summary
Two guidances issued by the US Food and Drug Administration on next-generation sequencing map out approaches for NGS developers to bring their products to market by relying on established standards and databases rather than new clinical studies to validate individual markers1-3.